Samsara BioCapital’s Arcellx ACLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-60,873
| Closed | -$6.99M | – | 25 |
|
|
2026
Q1 | $6.99M | Hold |
60,873
| – | – | 0.68% | 15 |
|
|
2025
Q4 | $3.97M | Sell |
60,873
-20,292
| -25% | -$1.62M | 0.41% | 18 |
|
|
2025
Q3 | $6.66M | Sell |
81,165
-20,292
| -20% | -$1.46M | 0.87% | 16 |
|
|
2025
Q2 | $6.68M | Sell |
101,457
-33,819
| -25% | -$2.11M | 1.37% | 12 |
|
|
2025
Q1 | $8.87M | Sell |
135,276
-118,365
| -47% | -$8.02M | 1.58% | 11 |
|
|
2024
Q4 | $19.5M | Sell |
253,641
-100,000
| -28% | -$8.64M | 2.67% | 9 |
|
|
2024
Q3 | $29.5M | Sell |
353,641
-100,000
| -22% | -$6.66M | 5.68% | 6 |
|
|
2024
Q2 | $25M | Hold |
453,641
| – | – | 5.24% | 5 |
|
|
2024
Q1 | $31.6M | Sell |
453,641
-6,800
| -1% | -$431K | 4.88% | 6 |
|
|
2023
Q4 | $25.6M | Sell |
460,441
-153,480
| -25% | -$6.92M | 3.98% | 5 |
|
|
2023
Q3 | $22M | Hold |
613,921
| – | – | 6.74% | 5 |
|
|
2023
Q2 | $19.4M | Sell |
613,921
-295,658
| -33% | -$11.3M | 3.41% | 6 |
|
|
2023
Q1 | $28M | Sell |
909,579
-47,872
| -5% | -$1.45M | 5.79% | 4 |
|
|
2022
Q4 | $29.7M | Sell |
957,451
-106,384
| -10% | -$2.44M | 6.38% | 3 |
|
|
2022
Q3 | $20M | Hold |
1,063,835
| – | – | 4.66% | 6 |
|
|
2022
Q2 | $19.2M | Buy |
1,063,835
+64,108
| +6% | +$827K | 5.13% | 5 |
|
|
2022
Q1 | $14M | Buy |
+999,727
| New | +$16.7M | 3.53% | 8 |
|
Other funds holding ACLX
Samsara BioCapital's ACLX Position: Q2 2026 in Review
Samsara BioCapital sold out of Arcellx (ACLX) in Q2 2026, closing a stake of 60,873 shares — an estimated $6.99M sold.
Samsara BioCapital first reported a position in ACLX in Q1 2022 and held it in 17 quarters. The position peaked at $31.6M in Q1 2024. 2 funds tracked by Wall St. Rank hold ACLX as of Q2 2026.
- Samsara BioCapital reported no remaining Arcellx position as of Q2 2026 after selling out during the quarter.
- Samsara BioCapital sold 60,873 Arcellx shares in Q2 2026, an estimated $6.99M.
- Samsara BioCapital first reported a position in Arcellx in Q1 2022 and held it in 17 quarters.
- Samsara BioCapital's Arcellx position peaked at $31.6M in Q1 2024.
- 2 funds tracked by Wall St. Rank held Arcellx as of Q2 2026.
Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.